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Abstract
A common problem in clinical trials is the missing data that occurs when patients do not complete
the study and drop out without further measurements. Missing data cause the usual statistical
analysis of complete or all available data to be subject to bias. There are no universally applicable
methods for handling missing data. We recommend the following: (1) Report reasons for dropouts
and proportions for each treatment group; (2) Conduct sensitivity analyses to encompass different
scenarios of assumptions and discuss consistency or discrepancy among them; (3) Pay attention to
minimize the chance of dropouts at the design stage and during trial monitoring; (4) Collect post-
dropout data on the primary endpoints, if at all possible; and (5) Consider the dropout event itself
an important endpoint in studies with many.
Introduction
With the exception of counting deaths from all causes, a
common problem in clinical trials is the missing data
caused by patients who do not complete the study in full
schedule and drop out of the study without further meas-
urements. Possible reasons for patients dropping out of
the study (the so-called 'withdrawals') include death, ad-
verse reactions, unpleasant study procedures, lack of im-
provement, early recovery, and other factors related or
unrelated to trial procedure and treatments. Missing data
in a study because of dropouts may cause the usual statis-
tical analysis for complete or available data to be subject
to a potential bias. This review attempts to raise the aware-
ness of the problem and to provide some general guidance
to clinical trial practitioners.
Examples
Withdrawals from clinical trials are ubiquitous. The Nu-
remberg Code, adopted in 1947, established principles of
ethical conduct in such trials. These principles demand
that the subject be given the choice stop participating at
any time during the clinical study. Under these principles,
the investigator is obliged to stop the experiment if injury
seems likely. I highlight just a few findings from recent ar-
ticles in the area of cardiovascular medicine for illustra-
tion.
Example 1:
A multicenter, randomized, double-blind, three parallel
groups trial to compare placebo, candesartan ciltexetil
and enalapril in patients with mild to moderate essential
hypertension [1]. The study randomized 205 to treat-
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ment, however, only 178 patients were evaluable by pro-
tocol at the end of an 8-week treatment period. 'The
remaining patients were excluded from the analysis of
blood pressure (BP) data because of major protocol viola-
tions, poor compliance with medical visits, or withdrawal
because of adverse events.'
Example 2:
A multicenter, randomized, open-label, parallel-design
study to compare the treatment effect of niacin and atorv-
astatin (for 12 weeks) on lipoprotein subfractions in pa-
tients with atherogenic dyslipidemia [2]. 'Of the total 108
patients randomized to treatment, 12 withdrew from the
study. Of those who withdrew, nine were due to adverse
events, two were lost to follow-up, and one did not return
for the final visit.'
Example 3:
A multicenter, randomized, double-blind, placebo-con-
trolled trial to assess treatment effect of pimobendan on
exercise capacity in patients with chronic heart failure [3].
'The primary pre-specified analysis of exercise time was
limited to those patients who had at least the first follow
up (four-week) exercise test carried out and had shown
good compliance up to the day of the test. If subsequent
tests were not performed, whatever the reason, or per-
formed although compliance between tests had been
poor, the last exercise time value obtained while compli-
ance was good was carried forward.' Two hundred and for-
ty of the 317 randomized patients had exercise test done
with good compliance at four, 12, and 24 weeks. Listed
reasons (and number of patients) for missing exercise
time data at 24 weeks were: 'exercise test not done due to
death' (n = 30), 'exercise testing contraindicated' (n = 9),
and 'exercise test not done for other reasons' (n = 10).
Example 4:
A randomized, double-blind study to compare nifed-
ipine-GITS and verapamil-SR on hemodynamics, left ven-
tricular mass, and coronary vasodilatory in patients with
advanced hypertension [4]. Fifty-four patients were rand-
omized after the placebo run-in phase. 'Twenty-four failed
to complete the (six-month) trial, and thus were not in-
cluded for analysis because of 1) withdrawal for sympto-
matic adverse effects, 2) lack of response, and 3) poor
compliance.' 'Consequently, there were 30 subjects with
sufficient data sets for inclusion in analyses.'
Example 5:
A randomized, double-blind, titration study of omapatri-
lat with hydrochlorothiazide in comparison with hydro-
chlorothiazide (HCTZ) plus placebo for the treatment of
hypertension [5]. After 2 weeks of placebo lead in and
four weeks of HCTZ period, 274 subjects were rand-
omized into three treatment groups. 'A total of 235 sub-
jects completed the (eight-week double-blind period)
study.'
Effect of withdrawals on the data analysis
To demonstrate with simple algebra the effects and key
statistical concepts surrounding missing data, I use the
data from Example 4 above. In that study, 54 patients
were randomized. However, only the 30 patients who
completed the trial were included in the paper's analysis.
The authors excluded from the analysis the other 24 pa-
tients who withdrew early because of adverse effects, lack
of response or poor compliance. Defining effective con-
trol of BP by the criteria of either maintaining diastolic
blood pressure (DBP) ≤  95 mmHg or achieving a least ≥
15 mmHg decrease in DBP, the authors summarized the
following results: 'Eighty per cent of randomized patients
completed the protocol with effective control of BP and
no side effects.' Obviously, the authors only counted 24
patients out of the 30 completers and obtained 80% and
ignored the 24 patients who dropped out prior to the
scheduled end of the study at six months. To distinguish
the different 24 patients in this example, we denote 24(cr)
for the former and 24(d) for the latter, that is, dropouts. It
is easily seen that the correct summary should be 24(cr)/54
= 44.4% completed the protocol with effective control of
BP and no side effects, rather than the reported 24(cr)/30
= 80%. (See Table 1.)
If the authors really intended to estimate the chance for
patients to have effective control of BP with no side effects
with the study therapies at Month 6 ('responders' in
brief), then we need to do more work. First, the calcula-
tion should always use 54 as the denominator because
that was the number of patients randomized to the study;
however, only 30 patients had BP measurement at Month
Table 1: Summary data from Diamond JA et al. [4]
Number of Patients
 (%)
Randomized 54
 (100)
Early withdrawal 24(d)
 (44.4)
Completed 6 months 30
 (55.6)
Completed 6 months with con-
trolled BP and no side effects
24(cr)
 (correct: 24(cr)/54 = 44.4%)
 (incorrect: 24(cr)/30 = 80%)Current Controlled Trials in Cardiovascular Medicine 2002, 3 http://cvm.controlled-trials.com/content/3/1/4
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6; of them, 24(cr) were responders. This means that the
true answer should be (24(cr)+?)/(30+24(d)) = (24+?)/54,
where the question mark represents the unknown number
of responders among the 24(d) withdrawals counted in
the denominator. Next, we calculate the extreme possibil-
ities as (a) (24(cr)+0)/54 = 44.4% and (b) (24(cr)+24)/54
= 48/54 = 88.9%.
In (a) we assumed that none of 24(d) withdrawals (0%)
responded, while in (b) we assume all 24(d) withdrawals
(100%) responded. Of course, we know that (b) is unre-
alistic since some people withdrew because of lack of re-
sponse and some because of side effects, but the paper did
not provide the exact numbers. In general, we usually do
not feel comfortable with either extreme, but we under-
stand that they provide an idea of the uncertainty in the
data because of withdrawals.
An estimate between the extremes is (c): to substitute the
unknown number by 24(d) ×  (24(cr)/30) = 24(d) ×  0.80 =
19.2, where 24(cr)/30 = 80% is the proportion of respond-
ers among those who completed the trial. That is, when
no particular information was available, we may assume
that the same proportion of patients (80%) among the
24(d)dropouts would have also responded, had they com-
pleted six months. Unsurprisingly, when we do the calcu-
lation, the estimate becomes (24(cr)+19.2)/54 = 43.2/54 =
80%, the same answer as that using only the completers.
In fact, a simple algebra can show that this is always so.
We can see that (c) is in-between (a) and (b), and in this
case, leans toward (b). See Table 2.
Notice that the paper reported that a proportion of 80%
of 'randomized patients completed the protocol with ef-
fective control of BP and no side effects' (as explained ear-
lier, the figure should instead be 44.4%), while the 80%
in (c) is an estimate of the chance of effective control of BP
without side effects with the study therapies at Month 6,
under an assumption of 'no information available for the
missing data'. We should not be confused with these two
'80%'. The former 80% is a wrong summary number; the
latter is an estimate of the quantity of interest with a par-
ticular assumption about the missing data. This assump-
tion is not likely to be appropriate for all the dropouts,
especially for those patients who dropped out because of
ineffective therapy; more discussion is given later. We do
not know whether the authors might have intended to
make the latter estimate but gave a wrong summary in-
stead.
Even more interesting and useful would be the same cal-
culations within each treatment group along with a com-
parison of the estimates. Unfortunately, the paper did not
give the number of dropouts according to their treatment
groups.
Using proportions simplifies the illustration, but the idea
can easily be conveyed to the estimation of continuous
data as well, such as BP, exercise time, hemodynamic
measures, and lipoprotein levels.
Lessons learned
Several points can be generalized from the simple illustra-
tion given above and closer examinations of the other ex-
amples.
• It does not take very much missing data to mislead an
investigator. A good principle to avoid being misled is to
always account for every subject randomized to the study
in the analysis. Using the total number of randomized
subjects in the denominator is a step towards accomplish-
ing this principle, whether it is to calculate an average or a
proportion. This principle is known as intent to treat
(ITT). However, the much harder job for ITT is to account
for the dropouts in the numerator. This requires further
consideration, which follows below.
Table 2: Illustration of different methods by example of data from Diamond JA et al. [4]
Responders+
Number of Patients Observed Estimated
  (a)&
Estimated
  (b)&
Estimated
  (c)&
Early withdrawal 24(d) ? 0 24 19.2
Completed 6 months 30 24(cr) 24(cr) 24(cr) 24(cr)
Total (%) 54(100) 24(cr)+? (?) 24 (44.4) 48 (88.9) 43.2 (80)
+Responder: effective control of BP and no side effects at month 6. & (a) and (b) assume two extreme informative missing models, (c) assumes miss-
ing completely at random (MCAR) model.Current Controlled Trials in Cardiovascular Medicine 2002, 3 http://cvm.controlled-trials.com/content/3/1/4
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• It is important to record and report the reasons for with-
drawal and the number of subjects in each category of
withdrawal according to their treatment group. The rea-
sons for patients dropping out can be used to help prop-
erly assess the nature of the missing data. For example, if
all the dropouts were because of a lack of response or side
effects, then the calculation in (a) would be appropriate.
In statistical terms, they would be called informative miss-
ing data. This is because useful information can be found
in the reason for the dropout and this can be used to esti-
mate the true response. Outcome-related dropouts are in-
formative and should not be disregarded in analytical
study without careful thought. In particular, when a pa-
tient dies, whatever the cause of the death might be, such
as in Example 3, all of the subsequent physiological and
quality of life data should not even be regarded as miss-
ing, but as having values equal to zero or the worst catego-
ry. When a patient's clinical status has reached a terminal
disease progression stage (such as New York Heart Associ-
ation class IV) and they are unable to perform exercise
testing, as in Example 3, the exercise time should also be
equal to zero seconds, and not simply regarded as missing
data. For the same reason, the remaining survival time af-
ter death (of any cause) would be zero days as well, not a
censored observation when doing, say Kaplan-Meier, sur-
vival analysis for an endpoint such as cardiovascular
death. Treating non-cardiovascular death as equivalent to
censoring because of loss-to-follow-up or end-of-observa-
tion for an endpoint of cardiovascular death has unfortu-
nately become a popular practice in many medical journal
articles. This needs to be corrected.
• The extreme calculations in (a) and (b) enable us to as-
sess the uncertainty of the data which contains missing
values, especially if we do the calculation for each treat-
ment group separately. The bias seen in the medical pub-
lishing industry in the decisions over which articles are
chosen for publication is a mirror image of the dropout
problem in patient studies. In the former, positive studies
have better chance of getting published, while negative
studies have a higher chance of being rejected. The same
is true for the latter: patients responding to treatment tend
to continue in the study, while patients failing to respond
tend to drop out prematurely. Using only the available
data or only the subgroup of those who complete the
study leads to a biased result. The approaches in (a) and
(b) take this consideration into account, although they
may also be biased by over-correction.
• The assumption underlying the approach in (c) is inter-
esting. When no particular information is known about
the missing data, we are essentially assuming that the
dropouts are not much different from the completers. This
is generally described statistically as missing completely at
random (MCAR), meaning that the process which caused
the missing data is not informative about the parameter
that we are trying to estimate. A good way to think of
MCAR is that the dropouts are a simple, random sample
of the study sample. Examples of MCAR include patients
who have moved away, or study that has closed and the
late entry of patients being administratively 'censored'.
We have seen the convenience of MCAR in the above illus-
tration: simply use the completers and we get the same re-
sult. However, whether this assumption is valid or not
should be examined carefully in each individual case. In
many situations, dropouts are not the same patient popu-
lation as those who stayed within the trial. MCAR certain-
ly is less restrictive than the assumptions in (a) or (b).
Still, other less restrictive assumptions than MCAR exist,
and these are discussed later.
• All three estimates given by (a), (b), and (c) are biased
to a certain extent. Had the authors given the detail about
the numbers of dropout categories of 'lack of response'
and 'side effects', a better estimate could be derived.
• We would certainly feel more comfortable with a study
conclusion when it is not altered by different approaches.
Sensitivity analysis is actually the best way to analyze data
in the presence of dropouts. Medical investigators should
consult with statisticians when dealing with missing data
because there are many possible methods available. Some
popular approaches are reviewed below.
More about methods handling missing data
Objectives
As in any data analysis, the first consideration is the objec-
tive of the analysis. In the presence of dropouts, there can
be two types of questions: (i) What would be the treat-
ment effect without dropouts? and (ii) What would be the
treatment effect in the presence of dropouts? Question (i)
is concerned with an ideal situation. It is also known as a
'question for explanatory trials' [6]. It is often concerned
with the human pharmacological properties of new drugs
under investigation rather than practical usage. Regarding
question (ii), we need to further differentiate two situa-
tions: patients drop out either (a) totally from the study
and no data are collected after withdrawal, or (b) merely
from the study assigned treatment with data still being
collected. For (b) there will be no missing data. If we can
design trials that will allow patients to be followed until
the end of the study despite the patient's lack of compli-
ance, then (ii) is a very practical question, also known as
the 'question for pragmatic trials' [7]. Prevention studies
with all-cause mortality as the primary endpoint usually
follow this design. However, other endpoints may also be
followed-up (until death) in such a design. A recent exam-
ple is [8], in which all participants, even those who dis-
continued treatment (lovastatin or placebo), were
contacted annually for vital status, cardiovascular events,Current Controlled Trials in Cardiovascular Medicine 2002, 3 http://cvm.controlled-trials.com/content/3/1/4
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and cancer history. Since no missing data would occur,
the design of (b) is highly recommended for all trials if at
all possible. In fact, the ITT principle originally aims to an-
swer question (ii) with (b) type of dropouts, where no
missing data would occur. However, more often than not
we face studies in which patients have withdrawn from
the study entirely and caused the missing data problem,
ie, type (a), as the Examples 1–5 (with the exception of Ex-
ample 3) above have demonstrated. Unless the patient's
clinical status does not permit further testing after discon-
tinuing the study treatment, type (a) dropout problem is
a common design flaw and should be corrected. Neverthe-
less, the problem of no follow-up data prevails in clinical
trials. For clinical trials conducted for drug registrations it
is possible that, in light of the International Conference
on Harmonization (ICH)-E9 guideline [9], the data anal-
yses have to address both questions (i) and (ii).
Imputation methods
The analyses illustrated in Table 2 were methods in the
general category of imputation. In general, the basic idea
of imputation is to fill in the missing data by using values
based on a certain model with assumptions. There are
methods based on a single imputation and methods
based on multiple imputation, which, instead of filling in
a single value for each missing value, replace each missing
value with a set of plausible values that represent the un-
certainty about the right value to impute. The attraction of
imputation is that once the missing data are filled-in (im-
puted), all the statistical tools available for the complete
data may be applied. Each method of (a), (b) and (c) in
Table 2 is a single simple imputation method, but togeth-
er they may be viewed as a 'multiple simple imputation'
method (as opposed to the 'proper multiple imputation'
method discussed below). The data in Table 2 only had
one time-point (Month 6) for analysis.
For longitudinal data with multiple time-points, the con-
ventional last-observation-carried-forward (LOCF) ap-
proach is a common practice of another simple
imputation. This approach was used by the authors in Ex-
amples 3 and 5. Attempting to follow the principle of ITT
to account for all randomized, LOCF method includes
every randomized subject who has at least one post-ther-
apy observation. LOCF is popular among practitioners be-
cause it is simple to put into effect and because of a
misconception that it is conservative (meaning working
against an effective treatment group). However, every im-
putation method implicitly or explicitly assumes a model
for the missing data. The LOCF assumes (unrealistically)
that the missing data after patient's withdrawal are the
same as the last value observed for that patient. The con-
sequence of this assumption is that it imputes data with-
out giving them within-subject variability and that it alters
the sample size.
Proper multiple imputation (PMI) methods are described
in [10] and [11], which use regression models to create
more than one imputed data sets and thus provide varia-
bility within and between imputations. PMI method has
long been a preferred approach in survey research. Its pop-
ularity has recently gainied in clinical trials since the
method became automated by commercial computer
software [12,13]. However, the complexity of regression
models used in PMI should be carefully thought through
by clinical trial practitioners, because the method assumes
that the missing data process can be fully captured by the
regression model employed on observed values. This as-
sumption is called missing at random (MAR). MAR essen-
tially says that the cause of the missing data may be
dependent on observed data (such as data of previous vis-
its) but must be independent of the missing value that
would have been observed. It is a less restrictive model
than MCAR, which says that the missing data cannot be
dependent on either the observed or the missing data. The
design suggested by Murray and Findlay [14], which
forced dropouts upon observing uncontrolled BP, uses the
MAR principle. When MAR or MCAR conditions are met,
model-based analyses can be appropriately performed
based on the observed data alone without further mode-
ling the missing data process.
Another imputation method, which is in-between the
LOCF and PMI, is the partial imputation (PI) or improved
LOCF method [15]. The idea of this method is quite sim-
ple. In LOCF, one imputes every missing visit time-point
by carrying the last observation forward until the end of
the study. Since LOCF requires the strong assumption of
stability, the more it imputes the more bias it introduces
if the assumption of stability does not hold. The method
of PI does not always carry the observations to the end
time-point of the study, but just far enough to balance the
dropout patterns between the treatment groups. The un-
derlying principle is that when the dropout patterns are
made almost identical between the treatment groups, the
relative comparison of the treatment effects will be less bi-
ased. Since PI does less imputation, it is less biased than
LOCF because the assumption of stability usually does
not hold. Some simulation results under various missing
data processes demonstrated the potential usefulness of PI
over the methods of using all available data and LOCF
[15]. However, more experience is still needed to test this
new method in practice.
Methods based on special missing data models
Other, more sophisticated methods based on statistical
models are available [16–18]; a technical review can be
found, for example, in [19] and [20]. No general compu-
ter programs are available to put them into effect though,
because every so-called informative missing data set re-
quires a unique model to describe it.Current Controlled Trials in Cardiovascular Medicine 2002, 3 http://cvm.controlled-trials.com/content/3/1/4
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Methods based on ranking observations
A large class of non-parametric methods is based on the
ranks or 'scores' of the observations instead of the actual
values. Commonly used non-parametric methods in clin-
ical trials include the Wilcoxon signed-rank test, Mann-
Whitney test, and so on. Example 3 also used a ranking
method after LOCF for a secondary analysis. Incorporat-
ing missing data into these methods can be easily done,
by ranking the missing data, according to the reasons for
withdrawals [21], and, in longitudinal study cases, the
time of withdrawal [22]. For example, death would be giv-
en the worst rank, followed by 'lack of efficacy', then 'ad-
verse reaction', 'patient refusal', and so on. Within the
same category of withdrawal, early dropouts would be giv-
en worse ranks than later dropouts. Ground rules for the
ranking should be set prior to unmasking the treatment
codes for data analyses to avoid being post-hoc. After
missing data are replaced by their ranks, the usual testing
procedure can be carried out. One major drawback in
these methods is that they do not provide any estimation
of the treatment effect in the original measurement unit,
because the data are replaced by the ranks.
All these methods, parametric or non-parametric, require
much closer collaboration between medical investigators
and statisticians. In the parametric case, the observed out-
come cannot provide statistical tests to select the missing
data models. In both cases, the validity of the various
models or ranking rules requires an examination of the
missing data information and strong faith in the reasons
given for the patients' withdrawal. Still, the main issue is
the question that these methods are addressing. They at-
tempt to follow the ITT principle (but with missing data)
to answer question (i) above, hoping that the dropouts
can hypothetically be removed by, say, a truly ITT design,
or by successfully using concurrent treatments for intoler-
able side effects without affecting the efficacy of the study
medication.
Composite comparisons
Many believe that removing the patient's dropout process
is not plausible in clinical practice. In this case, the drop-
out process itself may be an outcome of interest and not a
nuisance effect. For example, the US Federal Drug Associ-
ation's draft guidance on diabetes trials specifically re-
quested the consideration of dropouts as an endpoint
[23]. Therefore, the problem becomes a 'composite end-
points' issue. This is the approach taken in [24,25], and it
has lately been extended to modeling the joint distribu-
tion of the longitudinal and time-to-event data (ie, time to
withdrawal) [26,27]. In this setting, we would compare
the treatment groups with two aspects simultaneously: (a)
the chance (or duration) of complying with the prescribed
protocol and, (b) the outcome measure (eg, mean change
in systolic blood pressure) given the pattern of compli-
ance. The comparison (a) is straightforward by either the
standard binomial or survival techniques. The compari-
son (b) requires the same care as has been discussed here
previously, because, given the pattern of compliance, the
subgroup of patients has already been self-selected. The
randomization mechanism used for achieving compara-
bility between treatment groups is broken by the post-ran-
domization stratification of compliance. It is then
important to check the key outcome-correlated baseline
characteristics between the treatment groups for any in-
comparability among these subgroup patients. This was
done in Example 4 but not others. Recognizing that the
subgroups are no longer randomized, we should treat this
portion as a semi-observational study imbedded in the
randomized trial. Techniques used for analyzing observa-
tional studies should be applied to this part of compari-
son [28]. Generally speaking, in an observational study,
bias can only be reduced but not entirely eliminated by
methods of adjustment or matching. Sensitivity analysis
in this approach is to consider different baseline covari-
ates for matching or adjustment.
Conclusion
The issue of what to do about missing data caused by
dropouts in clinical trials is a research topic that is still un-
der development in statistical literature. As has been not-
ed in the ICH-E9 guideline [9], 'no universally applicable
methods of handling missing values can be recommend-
ed.' The issue of handling missing data is intrinsically dif-
ficult because it requires a large proportion of missing
data to investigate a method. On the other hand, a large
proportion of missing data would make a clinical study
less credible. The best available advice is to minimize the
chance of dropouts at the design stage and during trial
monitoring. A truly ITT design is absolutely encouraged.
This requires follow-up data to be collected even after pa-
tients discontinue the treatment, whenever the clinical
status of the patient permits. If it is anticipated that there
will be many dropouts, then perhaps the study's duration
should be shortened. Alternatively, the medical procedure
that is deemed to be the most likely cause of patients'
withdrawal should be altered. All data after death of any
cause should be given a value of zero instead of a blank.
Consideration may also be given to define an endpoint
(event), instead of a measurement value, as the primary
response variable, which can be determined even if the pa-
tient withdraws from the study. In an analysis, one should
be clear about the question or objective of the analysis
with missing data, and conduct sensitivity analysis with a
set of plausible, pre-specified models of the missing data.
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